Bio-Rad Laboratories anti-pertuzumab antibodies

Thursday, 03 February, 2022 | Supplied by: Bio-Rad Laboratories Pty Ltd


Bio-Rad Laboratories has introduced four inhibitory antibodies that are highly specific to pertuzumab (Perjeta). The ready-made antibodies inhibit the binding of the drug to its target, human epidermal growth factor 2 (HER2), enabling researchers to develop selective and sensitive assays for bioanalysis and drug monitoring of pertuzumab and its biosimilars.

Pertuzumab is a targeted cancer drug that binds to the HER2 protein, which is overexpressed in HER2-positive cancers, preventing cell growth and proliferation. The range of anti-pertuzumab antibodies includes monovalent Fab format antibodies suitable for the development of a pharmacokinetic bridging ELISA to measure free drug, as well as fully human IgG1 antibodies with varying levels of affinity, which can be used as a surrogate positive control or reference standard in an anti-drug antibody assay.

The antibodies are generated using the Human Combinatorial Antibody Libraries (HuCAL) and CysDisplay, a method of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant production method is designed to ensure a consistent and secure supply. The antibodies are approved for in vitro research purposes and for commercial services providing in vitro testing to support preclinical and clinical drug development.

Online: www.bio-rad.com
Phone: 02 9914 2800
Related Products

Cayman Chemical Bio-Active Lipid I Screening Library (96-Well)

Cayman Chemical's Bio-Active Lipid I Screening Library consists of 13 plates and contains...

Echelon Biosciences ionisable lipids

Echelon Biosciences' ionisable lipids are the key components of lipid nanoparticles (LNPs)...

BioStatus CyTRAK Orange fluorescent dye

BioStatus's CyTRAK Orange is a novel fluorescent dye that preferentially stains the nucleus...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd